secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001683168-23-005538
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW
--------------------------------------------------------------------------------

- Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.
- Royalty payments from Takeda sublicense were ~$0.7M in Q2 2023, up 56.2% from prior year.
- Cash position of ~$10.7M at quarter end; no outstanding debt.
- Executed first Collaborator SOW with VolitionRx and CLS for NETs-targeted CAR T cell therapies in solid cancers.
- Advancing DNase-based oncology program towards Phase 1 study for pancreatic carcinoma and other solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/0001683168-23-005538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer